



Financial Tear Sheet

Corporate Profile

AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives, all while delivering value to our shareholders.

Headquartered in Waltham, Massachusetts, with locations in Tucson, Arizona, and San Bruno, California, our products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. In addition, we help families preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders and have the potential to play a valuable role in the ongoing development of regenerative medicine.

Along with driving organic growth of our products, we seek to leverage our existing commercial infrastructure with additional commercial-stage products in our two current therapeutic areas and may consider late-stage development assets or seek opportunities in new therapeutic areas.

Linda Lennox
 Vice President, Investor
 Relations & Corporate
 Communications

Phone: 617-498-2846

Email:

lennenox@amagpharma.com

Stock Information

AMAG (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$18.35
Change (%)	0.00 (0.00%)
Volume	1,164,542
52 Week Low	\$16.00
Market Cap	\$643,082,980
Rolling EPS	-1.00
PE Ratio	0



Shares Outstanding 35,045,394

Data as of June 26, 2017 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News & Upcoming Events

June 26, 2017

There are currently no events scheduled.

AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector

June 01, 2017

AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio

May 31, 2017

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

SEC Filings

Filing Date	Form
June 23, 2017	S-8
June 05, 2017	4
May 25, 2017	SC 13G/A
May 24, 2017	8-K